$11.23
0.27% yesterday
Nasdaq, Jun 06, 10:00 pm CET
ISIN
BMG762791017
Symbol
ROIV
Sector
Industry

Roivant Sciences Stock price

$11.23
+0.17 1.54% 1M
-1.13 9.14% 6M
-0.60 5.07% YTD
+0.61 5.74% 1Y
+1.31 13.21% 5Y
+1.31 13.21% 10Y
+1.31 13.21% 20Y
Nasdaq, Closing price Fri, Jun 06 2025
+0.03 0.27%
ISIN
BMG762791017
Symbol
ROIV
Sector
Industry

Key metrics

Market capitalization $7.63b
Enterprise Value $2.75b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 94.57
P/S ratio (TTM) P/S ratio 262.80
P/B ratio (TTM) P/B ratio 1.67
Revenue growth (TTM) Revenue growth -76.72%
Revenue (TTM) Revenue $29.05m
EBIT (operating result TTM) EBIT $-1.11b
Free Cash Flow (TTM) Free Cash Flow $-844.05m
Cash position $4.89b
EPS (TTM) EPS $-0.24
P/E forward negative
P/S forward 317.30
EV/Sales forward 114.19
Short interest 9.57%
Show more

Is Roivant Sciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,823 stocks worldwide.

Roivant Sciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Roivant Sciences forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Roivant Sciences forecast:

Buy
90%
Hold
10%

Financial data from Roivant Sciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
29 29
77% 77%
100%
- Direct Costs 0.91 0.91
94% 94%
3%
28 28
74% 74%
97%
- Selling and Administrative Expenses 591 591
14% 14%
2,036%
- Research and Development Expense 550 550
4% 4%
1,895%
-1,100 -1,100
1% 1%
-3,785%
- Depreciation and Amortization 14 14
36% 36%
48%
EBIT (Operating Income) EBIT -1,114 -1,114
1% 1%
-3,834%
Net Profit -172 -172
104% 104%
-592%

In millions USD.

Don't miss a Thing! We will send you all news about Roivant Sciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Roivant Sciences Stock News

Neutral
Seeking Alpha
8 days ago
Roivant Sciences Ltd. (NASDAQ:ROIV ) Q4 2024 Earnings Conference Call May 29, 2025 8:00 AM ET Company Participants Stephanie Lee - Investor Relations Matt Gline - Chief Executive Officer Richard Pulik - Chief Financial Officer Conference Call Participants Brian Cheng - JPMorgan Chase & Co. David Risinger - Leerink Partners Dennis Ding - Jefferies Yaron Werber - TD Cowen Samuel Slutsky - LifeSci...
Neutral
GlobeNewsWire
9 days ago
BASEL, Switzerland and LONDON and NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2025, and provided a business update. Brepocitinib program progressing well with rapid enrollment in non-infectious uveitis (NIU) Phase 3 study and first patients dosed in cutaneous sarcoidosis (CS) proof-...
Neutral
GlobeNewsWire
22 days ago
BASEL, Switzerland and LONDON and NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 29, 2025, to report its financial results for the fourth quarter and fiscal year ended March 31, 2025, and provide a business update.
More Roivant Sciences News

Company Profile

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Head office Bermuda
CEO Matthew Gline
Employees 908
Founded 2014
Website roivant.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today